Indoco Remedies enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


1,973	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
44.9	25.9	12.1	22.1	11.9
−5.6	−7.2	−3.6	0.6	—
1,036	1,036	994	672	333
2,958	—	—	—	—
991	1,010	981	650	321
₹320.51	—	—	—	—

2,052	1,968	2,012	1,782	1,361
50.5%	52.6%	49.4%	37.7%	24.5%
0.35×	—	—	—	—

1.55×	—	—	—	—
17.54×	—	—	—	—
84.04×	—	—	—	—
66.18×	—	—	—	—
1,909	1,845	1,665	1,817	1,669
169	142	99.3	244	286
35.2	15.4	−14.6	152	215
—	192	94.9	157	179
44.7	44.7	−261	−271	−28.4
—	35.7	−261	−281	−35.6
—	148	356	427	207

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

INDOCO₹213.75

Indoco Remedies Limited

· Pharma & Health

₹ CrorePeersSAIPARENT PANACEABIO HIKAL WINDLAS HESTERBIO DCAL SYNCOMF SOLARAMcap ₹1,973 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	1,972.9
- Cash, Equiv & ST Investments	11.9	22.1	12.1	25.9	44.9
+ Minority Interest	—	0.6	-3.6	-7.2	-5.6
+ Total Debt	332.9	672.0	993.6	1,035.9	1,035.9
Enterprise Value	—	—	—	—	2,958.3
Net Debt (memo)	320.9	649.9	981.5	1,009.9	991.0
EV per Share	—	—	—	—	320.51

Total Capital	1,361.1	1,782.5	2,011.9	1,968.0	2,051.8
Total Debt/Total Capital	24.45	37.70	49.38	52.64	50.49
Total Debt/EV	—	—	—	—	0.35

EV/Sales	—	—	—	—	1.55
EV/EBITDA	—	—	—	—	17.54
EV/EBIT	—	—	—	—	84.04
EV/Free Cash Flow	—	—	—	—	66.18
Reference Items — Trailing FY Values
Sales	1,668.6	1,817.3	1,664.9	1,845.3	1,908.6
EBITDA	286.1	244.3	99.3	141.8	168.7
EBIT	215.5	152.4	-14.6	15.4	35.2
Operating Cash Flow	178.8	156.7	94.9	192.2	—
Free Cash Flow	-28.4	-270.6	-261.2	44.7	44.7
FCFF (free cash flow to the firm)	-35.6	-280.9	-261.2	35.7	—
Capital Expenditure	207.3	427.3	356.2	147.5	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.